Literature DB >> 1349669

Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism.

Z Laron1, S Anin, Y Klipper-Aurbach, B Klinger.   

Abstract

Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349669     DOI: 10.1016/0140-6736(92)91594-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

1.  Familial growth hormone insensitivity syndrome.

Authors:  A H Zargar; B A Laway; S R Masoodi; M Salahuddin; M A Siddiqui
Journal:  Indian J Pediatr       Date:  1995 Mar-Apr       Impact factor: 1.967

2.  Familial growth hormone insensitivity syndrome.

Authors:  A H Zargar; B A Laway; S R Masoodi; M Salahuddin; M A Siddiqui
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

Review 3.  Clinical use of somatomedin-1: yes or no?

Authors:  Z Laron
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 4.  Somatomedin-1 (insulin-like growth factor-I) in clinical use. Facts and potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

5.  Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Authors:  Yingjie Wu; Hui Sun; Jelena Basta-Pljakic; Luis Cardoso; Oran D Kennedy; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

6.  Renal function in Laron syndrome patients treated by insulin-like growth factor-I.

Authors:  B Klinger; Z Laron
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

7.  Growth curves for Laron syndrome.

Authors:  Z Laron; P Lilos; B Klinger
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

8.  Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

Authors:  M A Hussain; O Schmitz; A Mengel; Y Glatz; J S Christiansen; J Zapf; E R Froesch
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans.

Authors:  M A Hussain; O Schmitz; A Mengel; A Keller; J S Christiansen; J Zapf; E R Froesch
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.